

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549

Status	RECRUITING
Phase	Phase 2
Sponsor	Galimedix Therapeutics Inc
Enrollment	110 participants

Key Eligibility Criteria

Inclusion (15)

- e55years of age
 - Willing and able to provide written informed consent
 - Willing and able to comply with the study schedule and study assessments
 - Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution
 - BCVA of e50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline
- ... and 10 more (see full listing online)

Exclusion (29)

- Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline
 - History of laser therapy in the macular region, regardless of indication
 - History of herpes zoster
 - Ophthalmic disease or condition that requires or is likely to require surgery during the study period
 - GA with cumulative area $\lt 1.25$ mm²
- ... and 24 more (see full listing online)

Locations (14 total)

Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
Bay Area Retina Associates, Walnut Creek, California, United States
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
... and 11 more locations